Option Care Health (OPCH) Q4 2025: $70M Stellara Headwind Absorbed as Cash Flow Targets Rise 30%
Option Care Health absorbed a $70 million Stellara biosimilar headwind yet reaffirmed 2026 guidance, underscoring operational resilience and robust payer partnerships. Cash flow generation is set for a sharp rebound, with new site-of-care programs and advanced practitioner clinics supporting growth despite ongoing reimbursement and mix pressures. Investors should focus on the company’s ability to leverage its national scale and local responsiveness as biosimilar dynamics and payer cost demands intensify through 2026.
Summary
- Stellara Transition Managed: Biosimilar adoption weighed on revenue, but execution offset margin risk.
- Payer Partnerships Deepen: New site-of-care programs and non-traditional payer channels expand reach.
- Cash Flow Acceleration: Working capital initiatives target >30% growth in operating cash flow for 2026.
Performance Analysis
Option Care Health delivered 13% revenue growth for 2025, driven by balanced expansion in both acute and chronic therapy segments. Acute revenue grew in the mid-teens, supported by continued share gains as competitors exited, while chronic therapies posted low double-digit growth. The Stellara, chronic inflammatory drug, biosimilar shift created a 160 basis point revenue headwind and a $70 million impact to gross profit, but management executed to plan and contained the margin impact to targeted levels.
Gross profit dollars rose 7.4% and SG&A expense as a percent of sales improved by 50 basis points, reflecting productivity gains and efficiency investments across the platform. Adjusted EBITDA increased 6%, with margin holding at 8.3%, and adjusted diluted EPS rose 9% as share repurchases supported per-share results. Cash flow from operations reached $258 million, below original guidance due to strategic inventory buys and working capital ramp to support high-value, limited distribution drugs. The company ended the year with a net leverage ratio of 2.0x, maintaining financial flexibility for continued investment.
- Acute Volume Tailwind: Acute segment strength continued as the company capitalized on competitor exits and payer demand for lower-cost settings.
- Chronic Mix Headwind: Chronic therapy growth was offset by biosimilar adoption, pressuring gross margins but in line with guidance.
- Efficiency Initiatives: 40% of claims are now processed without human intervention, supporting margin leverage and scalability.
Strategic inventory purchases and working capital investment weighed on 2025 cash flow, but management expects >$340 million in 2026, a 30%+ increase, as timing effects normalize and operational discipline improves. Share repurchases exceeded $300 million, and the board expanded authorization by $500 million, signaling ongoing commitment to capital return.
Executive Commentary
"Option Care Health is uniquely positioned as the nation's largest independent provider of home and alternate site infusion therapies. We built a strategy on a national scale that starts with putting the patient at the center, provides high-quality care with cost advantages, and fosters clinical innovation with local responsiveness."
John Rademacher, President and Chief Executive Officer
"We are already executing on initiatives to reduce our working capital with a focus on inventory as we believe a significant portion is timing related. We are also taking a fresh look at our processes and practices around working capital management to continue driving our strong cash conversion cycle."
Meenal, Chief Financial Officer
Strategic Positioning
1. Payer and Referral Channel Expansion
Option Care Health deepened payer alignment, adding five new regional and two non-traditional payer programs, including direct-to-employer and convener relationships. These programs support site-of-care initiatives, enabling payers to shift care to lower-cost settings and reduce medical loss ratios. The company’s embedded nurse and transition support capabilities are increasingly valued by both payers and hospital systems seeking to manage cost and quality under capitated and DRG payment models.
2. Advanced Practitioner and Clinic Network Buildout
Investments in ambulatory infusion clinics and advanced practitioner models accelerated, with over 25 centers now operational and 34% of nursing visits occurring in these settings. The acquisition of Intramed Plus drove a 25% increase in clinic visits at those sites, and ongoing conversion of existing facilities is expected to further boost capacity, efficiency, and patient choice. Utilization gains are improving nursing productivity by approximately 20% at mature sites.
3. Technology and AI-Driven Efficiency
Automation initiatives are scaling, with 40% of claims processed touchlessly and AI tools deployed for invoice processing, cash posting, and workforce optimization. These investments are designed to enable growth without proportional labor increases, enhance quality, and support a capital-light business model. Expansion into agentic AI for call centers and inventory management is underway, with future clinical applications under evaluation.
4. Limited Distribution and Rare Drug Platform
Option Care Health operates over 20 enhanced programs for rare and limited distribution drugs, with two new platforms set to launch in 2026. These high-value therapies require upfront working capital but offer strategic differentiation and deepen relationships with pharma manufacturers seeking national scale and clinical expertise for new product launches.
5. Capital Allocation Discipline
Capital allocation priorities remain consistent: organic investment, disciplined M&A, and opportunistic share repurchase. The Intramed Plus acquisition exceeded expectations, and the company continues to evaluate additional tuck-in opportunities while maintaining a strict focus on strategic and financial fit. Share buybacks remain a lever as cash generation accelerates in 2026.
Key Considerations
Option Care Health’s 2025 execution highlights the company’s ability to manage through industry headwinds while investing for sustainable growth. The following considerations frame the investment context for 2026:
- Biosimilar Revenue Headwind Absorbed: Stellara conversion led to a $70 million revenue impact, but management contained margin erosion and expects the bulk of this pressure to subside after 2026.
- Growth in High-Complexity Therapies: Pipeline of infused and injectable drugs, especially in neurology, autoimmune, oncology, and rare diseases, is expected to expand the addressable market and reinforce payer and pharma partnerships.
- Cash Flow Rebound: Working capital normalization and inventory management initiatives are set to drive a >30% increase in operating cash flow for 2026, supporting both organic and inorganic growth levers.
- Operational Leverage from Technology: AI and automation are delivering measurable productivity gains, with further upside as adoption widens across patient administration and support functions.
Risks
Key risks include continued reimbursement pressure from biosimilar adoption, margin dilution from mix shift toward lower-priced therapies, and execution risk as the company scales new clinic models and payer programs. Regulatory changes, especially around Medicare Advantage and site neutrality, could further impact pricing and care delivery economics. Competition for limited distribution drugs and evolving payer contracting models add uncertainty to growth and margin forecasts.
Forward Outlook
For Q1 2026, Option Care Health expects:
- Revenue growth in line with the $5.8 to $6 billion full-year range, with Q1 the seasonally weakest cash flow period.
- Gross profit headwind from Stellara biosimilar shift to be evenly distributed across quarters.
For full-year 2026, management reaffirmed guidance:
- Revenue: $5.8 to $6 billion (4% growth at midpoint, with 400 bps Stellara headwind)
- Adjusted EBITDA: $480 to $505 million
- Adjusted diluted EPS: $1.82 to $1.92
- Operating cash flow: at least $340 million
Management emphasized confidence in the outlook, citing strong payer alignment, robust pipeline, and ongoing operational discipline. Inventory and working capital normalization, as well as continued AI-driven efficiency gains, are expected to drive results in the back half of the year.
- Stellara headwind expected to subside post-2026
- Clinic expansion and payer programs remain key growth levers
Takeaways
Option Care Health’s 2025 performance demonstrates resilience amid biosimilar and reimbursement headwinds, with strategic investments positioning the company to capitalize on payer cost pressures and specialty drug pipeline growth.
- Margin Management: Despite a $70 million Stellara impact, Option Care Health maintained margin discipline and operational leverage.
- Payer and Pharma Partnerships: Expansion into non-traditional payer channels and rare drug programs enhances platform stickiness and long-term growth potential.
- 2026 Focus: Investors should watch for cash flow execution, advanced clinic utilization, and biosimilar mix impacts as Option Care Health navigates a shifting reimbursement environment.
Conclusion
Option Care Health enters 2026 with its core platform intact, strong payer relationships, and a clear path to higher cash generation. While biosimilar and mix pressures remain, the company’s investments in technology, clinical capacity, and payer partnerships position it to outgrow industry peers and respond to evolving healthcare economics.
Industry Read-Through
Option Care Health’s results reinforce several sector-wide trends: the shift of infusion therapies to lower-cost settings, the growing power of payers in dictating site-of-care and drug mix, and the need for scale and technology to manage cost and complexity. Biosimilar adoption is accelerating margin compression across specialty drug channels, while payer and employer direct contracting is reshaping referral and reimbursement dynamics. Competitors lacking scale, payer alignment, or automation will face increasing pressure as the market consolidates and care delivery models evolve. These dynamics will shape not only infusion providers but also specialty pharmacy, home health, and outpatient care peers in the coming years.